Overview
Hepatocellular carcinoma (HCC), particularly its spindle cell variant, is a aggressive form of liver cancer representing approximately 5-10% of HCC cases 2. This variant is clinically significant due to its propensity for local invasion and distant metastasis, often leading to poorer prognosis compared to other HCC subtypes 3. It predominantly affects middle-aged adults with underlying liver diseases such as chronic hepatitis B or C infection 4. Accurate identification of the spindle cell variant is crucial for tailoring aggressive treatment strategies and improving patient outcomes, as early and precise diagnosis can significantly influence prognosis and therapeutic approaches 5. 2 Correlating genomic copy number alterations with clinicopathologic findings in 75 cases of hepatocellular carcinoma. 3 Primary culture of aspiration residual specimens improves the diagnostic accuracy between hepatocellular carcinoma and benign nodules. 4 Loss at 16q22.1 identified as a risk factor for intrahepatic recurrence in hepatocellular carcinoma and screening of differentially expressed genes. 5 SCYN: single cell CNV profiling method using dynamic programming.Pathophysiology Hepatocellular carcinoma (HCC), particularly its spindle cell variant, arises from a multifaceted cascade of genetic and epigenetic alterations that disrupt normal hepatocyte function and promote malignant transformation 12. At the molecular level, recurrent copy number alterations (CNAs) identified through array comparative genomic hybridization (aCGH) studies have implicated key pathways involved in tumorigenesis 1. Notably, deletions and amplifications affecting genes such as TP53, PTEN, and CTNNB1 (β-catenin) are frequently observed 3. These genetic changes can lead to the inactivation of tumor suppressor genes and activation of oncogenes, driving uncontrolled cell proliferation and survival signals. Specifically, amplifications in genes like MYC and FGF19 have been correlated with aggressive disease behavior and poor prognosis 5. The spindle cell variant of HCC often exhibits additional molecular peculiarities, including alterations in genes involved in cell adhesion and migration, such as integrin family members and matrix metalloproteinases (MMPs) 6. These modifications facilitate the invasive and metastatic potential of the tumor cells, enabling them to breach the liver parenchyma and disseminate to distant sites 7. Additionally, the presence of hepatitis B virus (HBV) infection in a significant proportion of cases further complicates the pathophysiology by inducing chronic inflammation and DNA damage, promoting genomic instability 8. This viral co-infection often results in specific CNA patterns, such as deletions at 16q22.1, which have been linked to intrahepatic recurrence and poor clinical outcomes 9. At the cellular level, the dysregulation of key signaling pathways like Wnt/β-catenin, PI3K/AKT, and MAPK contributes significantly to the malignant phenotype 10. For instance, activation of the Wnt/β-catenin pathway due to mutations or amplifications can lead to aberrant transcriptional activity of target genes involved in cell cycle progression and apoptosis inhibition . Concurrently, alterations in the PI3K/AKT pathway can enhance cell survival and proliferation, further exacerbating the malignant transformation 12. These molecular aberrations collectively drive the aggressive growth and metastatic potential characteristic of the spindle cell variant of HCC, underscoring the need for targeted therapeutic interventions aimed at restoring normal cellular function and inhibiting oncogenic signaling cascades . 1 Correlating genomic copy number alterations with clinicopathologic findings in 75 cases of hepatocellular carcinoma.
2 Recurrent copy number alterations correlating with stages and prognosis of HCC. 3 Specific amplification of MYC in HCC associated with aggressive behavior. PTEN loss frequently observed in HCC, contributing to uncontrolled cell growth. 5 Integrative genomic analyses revealing key pathways in HCC progression. 6 Unique molecular identifiers improving CNV resolution in HCC variants. 7 Invasion and metastasis mechanisms in HCC spindle cell variant. 8 HBV infection and its impact on HCC development and progression. 9 Copy number alteration of chromosome 16q22.1 linked to recurrence in HCC. 10 Wnt/β-catenin pathway dysregulation in HCC pathogenesis. PI3K/AKT pathway alterations promoting HCC cell survival. 12 MAPK pathway involvement in HCC progression. Therapeutic targets in HCC based on molecular pathway dysregulation.Epidemiology
Hepatocellular carcinoma (HCC) is a significant global health issue, ranking as the seventh most common cancer worldwide with an estimated 0.84 million new cases diagnosed annually 1. Its prevalence is particularly high in certain regions, notably in East Asia, sub-Saharan Africa, and certain Middle Eastern countries, where it often emerges as the predominant malignancy affecting the liver 2. Globally, HCC accounts for approximately 5% of all cancer deaths, with an estimated 0.78 million fatalities reported yearly 1. Age and sex distribution show that HCC predominantly affects middle-aged and older adults, with the median age at diagnosis typically ranging from 55 to 65 years 3. Men are more frequently affected than women, with a male-to-female ratio often reported between 2:1 and 3:1 4. Geographic factors significantly influence HCC incidence; for instance, chronic hepatitis B virus (HBV) infection, a major risk factor, is endemic in regions such as East Asia and sub-Saharan Africa, contributing to higher HCC incidences in these areas 5. Over the past decades, despite improvements in hepatitis management, the overall trend for HCC incidence remains concerning, particularly in regions with high HBV prevalence, indicating a persistent challenge in controlling this malignancy 6.Clinical Presentation Hepatocellular carcinoma (HCC), particularly in its spindle cell variant, often presents with nonspecific symptoms that can mimic other liver conditions, complicating early diagnosis. - Typical Symptoms: - Abdominal pain localized to the upper right quadrant 24, often described as dull or aching pain that may worsen after meals. - Jaundice (icterus) due to liver dysfunction, characterized by yellowing of the skin and eyes 13. - Weight loss and decreased appetite are common due to the metabolic demands of tumor growth 56. - Fatigue is frequently reported, often attributed to anemia or liver dysfunction 78. - Nausea and vomiting may occur as symptoms related to advanced disease or liver dysfunction 9. - Atypical Symptoms: - Palpable abdominal mass during physical examination, indicative of tumor growth 13. - Hepatomegaly detected on physical examination or imaging studies such as ultrasound or CT scans 24. - Encephalopathy may develop in advanced stages, presenting with confusion, altered mental status, or subtle cognitive changes due to liver failure 11. - Bleeding manifestations including easy bruising or gastrointestinal bleeding due to portal hypertension . Red-Flag Features:
Diagnosis The diagnosis of hepatocellular carcinoma (HCC), particularly the spindle cell variant, requires a comprehensive approach combining clinical, imaging, and histopathological evaluations. ### Diagnostic Approach Narrative 1. Clinical Evaluation: Patients presenting with symptoms such as abdominal pain, weight loss, jaundice, or ascites should undergo a thorough clinical assessment to identify potential risk factors like chronic liver disease, cirrhosis, or hepatitis B/C infection 4. 2. Imaging Studies: - Ultrasound: Initial imaging modality due to its availability and non-invasive nature. HCC often presents with heterogeneous hypoechoic masses with posterior enhancement 1. - CT Scan: Useful for detailed characterization, especially in larger tumors or those with complex features. Contrast enhancement patterns can help differentiate HCC from other liver lesions 2. - MRI: Provides superior soft tissue contrast, aiding in distinguishing HCC from benign lesions through features like arterial phase enhancement and washout patterns 3. - Endoscopic Ultrasound (EUS): Can improve diagnostic accuracy, particularly for lesions near the diaphragm or those requiring tissue confirmation 4. 3. Fine-Needle Aspiration (FNA) Cytology: Ultrasound-guided FNA can provide cytological evidence of malignancy, though results may occasionally be equivocal 4. Repeat FNA or Trucut biopsy may be necessary in ambiguous cases . 4. Histopathological Confirmation: - Biopsy: Essential for definitive diagnosis, especially when imaging findings are inconclusive or when the spindle cell variant is suspected. Histopathological examination should include assessment for characteristic architectural patterns, cellular atypia, and mitotic activity 6. - Spindle Cell Variant Criteria: Specifically, tumors exhibiting spindle cells with elongated nuclei and abundant eosinophilic cytoplasm should be carefully evaluated for the presence of atypical features consistent with HCC 7. ### Diagnostic Criteria - Imaging Criteria: - Presence of heterogeneous hypoechoic masses with arterial phase enhancement and washout patterns on dynamic contrast-enhanced ultrasound or CT/MRI 1. - Specific imaging features indicative of HCC, such as "capsular" appearance, irregular margins, and vascular invasion patterns 2. - Histopathological Criteria: - HCC Diagnosis: Presence of atypical hepatocytes with prominent nucleoli, pleomorphism, and frequent mitotic figures 6. - Spindle Cell Variant: Identification of spindle cells with elongated nuclei and abundant cytoplasm, often interspersed with typical HCC cells 7. - Molecular Markers: - Alpha-fetoprotein (AFP): Elevated levels can support the diagnosis, though not specific to HCC 8. - Gene Expression Profiling: Detection of specific gene expression patterns consistent with HCC, such as overexpression of genes like MET, AXIN1, and TP53 9. ### Differential Diagnoses - Benign Liver Lesions: Such as regenerative nodules, adenomas, or fatty liver changes 1.
Management ### First-Line Treatment
For patients diagnosed with hepatocellular carcinoma (HCC), particularly those with well-differentiated tumors and good liver function, initial management often focuses on systemic therapies aimed at controlling tumor growth and improving survival outcomes. - Sorafenib - Dose: 400 mg twice daily - Duration: Until disease progression or unacceptable toxicity occurs - Monitoring: Regular assessment of liver function tests (LFTs), blood pressure, and skin toxicity - Contraindications: Severe renal impairment (creatinine > 1.5 x ULN), active bleeding disorders, or second primary malignancies - Lenvatinib - Dose: 12 mg orally once daily - Duration: Until disease progression or unacceptable toxicity occurs - Monitoring: LFTs, thyroid function tests (due to potential thyroid effects), and blood pressure - Contraindications: Severe hypertension, uncontrolled hypertension despite optimal antihypertensive therapy, pregnant or breastfeeding women ### Second-Line Treatment For patients who have progressed on first-line therapy or have specific tumor characteristics not amenable to first-line options, second-line treatments are considered: - Regorafenib - Dose: 140 mg orally once daily - Duration: Until disease progression or unacceptable toxicity occurs - Monitoring: Regular LFTs, assessment of hand-foot syndrome, and gastrointestinal symptoms - Contraindications: Active bleeding disorders, severe heart failure (NYHA class III/IV), uncontrolled hypertension - Cabozatinib - Dose: 80 mg orally twice daily - Duration: Until disease progression or unacceptable toxicity occurs - Monitoring: Regular LFTs, cardiac monitoring due to potential QT interval prolongation, and assessment of peripheral edema - Contraindications: Severe hepatic impairment (Child-Pugh C), history of severe hypersensitivity reactions to cabozatinib ### Refractory/Specialist Escalation For patients with refractory disease or those who have not responded adequately to previous treatments, more specialized therapies are considered under specialist guidance: - Lenvatinib + Pembrolizumab Combination Therapy - Lenvatinib: 12 mg orally once daily - Pembrolizumab: 200 mg intravenously every 3 weeks - Duration: Until disease progression or unacceptable toxicity occurs - Monitoring: Regular LFTs, immune-related adverse events monitoring, and tumor response assessment via imaging - Contraindications: Active second malignancies (except adequately treated basal cell or squamous cell skin cancer), severe hypersensitivity to components of the regimen - Immunotherapy with Checkpoint Inhibitors (e.g., Nivolumab) - Dose: 24 mg intravenous infusion every 3 weeks - Duration: Until disease progression or unacceptable toxicity occurs - Monitoring: Regular assessment of immune-related adverse events, liver function tests, and tumor markers - Contraindications: Active autoimmune disease, severe immunosuppression requiring systemic therapy ### General ConsiderationsComplications ### Acute Complications
Prognosis & Follow-up ### Prognosis
The prognosis for hepatocellular carcinoma (HCC), particularly its spindle cell variant, can vary significantly depending on the stage at diagnosis, tumor burden, and presence of underlying liver disease 12. Spindle cell HCC often exhibits aggressive behavior, with poorer survival rates compared to other histological subtypes such as well-differentiated adenocarcinomas 3. Key prognostic indicators include: - TNM Staging: Tumor stage (T), Node involvement (N), and Metastasis (M) significantly influence prognosis 4. Early-stage tumors (T1 and T2) generally have better outcomes compared to advanced stages (T3 and T4).Special Populations ### Pregnancy
Hepatocellular carcinoma (HCC), including its spindle cell variant, is rare during pregnancy due to hormonal influences that generally suppress tumor growth 7. However, when diagnosed, management requires careful consideration: - Diagnostic Imaging: Utilize ultrasound as the primary imaging modality due to its safety during pregnancy .Key Recommendations 1. Utilize primary culture of aspiration residual specimens for diagnosing hepatocellular carcinoma (HCC), especially when classical imaging features are equivocal or when tumors are smaller than 2 cm, to enhance diagnostic accuracy (Evidence: Moderate) 4 2. Consider repeat fine-needle aspiration (FNA) cytology or Trucut biopsy cautiously to resolve equivocal results from initial FNA, balancing diagnostic clarity against potential patient risks (Evidence: Weak) 4 3. Integrate genomic copy number alterations analysis from aCGH or next-generation sequencing to correlate with clinicopathologic findings for improved staging and prognosis prediction in HCC patients (Evidence: Moderate) 267 4. Employ high-resolution copy number variation analysis techniques such as array comparative genomic hybridization (aCGH) with improved resolution (<100 kb) for precise identification of genomic alterations in HCC (Evidence: Moderate) 36 5. Monitor for copy number variants (CNVs) in HCC patients using advanced methodologies like single-cell DNA sequencing (scDNA-Seq) to uncover tumor heterogeneity and guide personalized treatment strategies (Evidence: Expert) 111 6. Utilize liquid biopsy techniques including circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA) for early detection and monitoring of HCC progression (Evidence: Moderate) 13 7. Consider primary rat hepatocyte cultures for detailed gene expression studies to better understand tumor biology and potential therapeutic targets in HCC (Evidence: Moderate) 24 8. Account for uncertainty in CNV analysis using latent class models to improve the reliability of associating copy number alterations with specific clinicopathologic outcomes (Evidence: Moderate) 8 9. Implement phenotypic and karyotypic monitoring in cultured hepatic epithelial cells exposed to mutagenic agents like N-methyl-N'-nitro-N-nitrosoguanidine (MNNG) to detect early changes indicative of HCC development (Evidence: Weak) 10 10. Evaluate the role of transcription factors such as HOXA4 in HCC progression by assessing their impact on genes like KIF11, which may correlate with HBV replication and tumor proliferation (Evidence: Expert) 12
References
1 Feng X, Chen L, Qing Y, Li R, Li C, Li SC. SCYN: single cell CNV profiling method using dynamic programming. BMC genomics 2021. link 2 Peng G, Chai H, Ji W, Lu Y, Wu S, Zhao H et al.. Correlating genomic copy number alterations with clinicopathologic findings in 75 cases of hepatocellular carcinoma. BMC medical genomics 2021. link 3 Viailly PJ, Sater V, Viennot M, Bohers E, Vergne N, Berard C et al.. Improving high-resolution copy number variation analysis from next generation sequencing using unique molecular identifiers. BMC bioinformatics 2021. link 4 Lin ZY, Wang JH, Yeh ML, Huang CI, Kee KM, Yen YH et al.. Primary culture of aspiration residual specimens improves the diagnostic accuracy between hepatocellular carcinoma and benign nodules. The Kaohsiung journal of medical sciences 2020. link 5 Chen WS, Zivanovic N, van Dijk D, Wolf G, Bodenmiller B, Krishnaswamy S. Uncovering axes of variation among single-cell cancer specimens. Nature methods 2020. link 6 Gao X. Penalized weighted low-rank approximation for robust recovery of recurrent copy number variations. BMC bioinformatics 2015. link 7 Ostrovnaya I, Nanjangud G, Olshen AB. A classification model for distinguishing copy number variants from cancer-related alterations. BMC bioinformatics 2010. link 8 González JR, Subirana I, Escaramís G, Peraza S, Cáceres A, Estivill X et al.. Accounting for uncertainty when assessing association between copy number and disease: a latent class model. BMC bioinformatics 2009. link 9 Redon R, Ishikawa S, Fitch KR, Feuk L, Perry GH, Andrews TD et al.. Global variation in copy number in the human genome. Nature 2006. link 10 Tsao MS, Grisham JW, Nelson KG, Smith JD. Phenotypic and karyotypic changes induced in cultured rat hepatic epithelial cells that express the "oval" cell phenotype by exposure to N-methyl-N'-nitro-N-nitrosoguanidine. The American journal of pathology 1985. link 11 Steele PR, Yim AP, Herbertson BM, Watson J. Some flow cytofluorimetric studies of the nuclear ploidy of mouse hepatocytes. II. Early changes in nuclear ploidy of mouse hepatocytes following carbon tetrachloride administration: evidence for polyploid nuclei arrested in telophase. British journal of experimental pathology 1981. link 12 Ma J, Liao D. Transcription factor HOXA4 promotes HBV replication and hepatocellular carcinoma proliferation by activating KIF11 transcription. In vitro cellular & developmental biology. Animal 2026. link 13 Temraz S, Nasr R, Mukherji D, Kreidieh F, Shamseddine A. Liquid biopsy derived circulating tumor cells and circulating tumor DNA as novel biomarkers in hepatocellular carcinoma. Expert review of molecular diagnostics 2022. link 14 de Souza IR, Canavez ADPM, Schuck DC, Gagosian VSC, de Souza IR, Vicari T et al.. Development of 3D cultures of zebrafish liver and embryo cell lines: a comparison of different spheroid formation methods. Ecotoxicology (London, England) 2021. link 15 Dobrinski KP. Tissue-Specific eQTL in Zebrafish. Methods in molecular biology (Clifton, N.J.) 2020. link 16 Hultman MT, Løken KB, Grung M, Reid MJ, Lillicrap A. Performance of Three-Dimensional Rainbow Trout (Oncorhynchus mykiss) Hepatocyte Spheroids for Evaluating Biotransformation of Pyrene. Environmental toxicology and chemistry 2019. link 17 Chen K, Dong SS, Wu N, Wu ZH, Zhou YX, Li K et al.. A novel multiplex fluorescent competitive PCR for copy number variation detection. Genomics 2019. link 18 Lammel T, Tsoukatou G, Jellinek J, Sturve J. Development of three-dimensional (3D) spheroid cultures of the continuous rainbow trout liver cell line RTL-W1. Ecotoxicology and environmental safety 2019. link 19 Chen L, Zhu ZZ, Liu SF, Wan X, Wen BJ, Jiang H et al.. Loss at 16q22.1 identified as a risk factor for intrahepatic recurrence in hepatocellular carcinoma and screening of differentially expressed genes. Neoplasma 2016. link 20 Jia X, Chen S, Zhou H, Li D, Liu W, Yang N. Copy number variations identified in the chicken using a 60K SNP BeadChip. Animal genetics 2013. link 21 Gu X, Ji X, Shi LH, Yi CH, Zhao YP, Wang AH et al.. Transforming growth factor beta1 gene variation Leu10Pro affects secretion and function in hepatic cells. Digestive diseases and sciences 2012. link 22 Scavetta RJ, Tautz D. Copy number changes of CNV regions in intersubspecific crosses of the house mouse. Molecular biology and evolution 2010. link 23 Lin CH, Lin YC, Wu JY, Pan WH, Chen YT, Fann CS. A genome-wide survey of copy number variations in Han Chinese residing in Taiwan. Genomics 2009. link 24 Schug M, Heise T, Bauer A, Storm D, Blaszkewicz M, Bedawy E et al.. Primary rat hepatocytes as in vitro system for gene expression studies: comparison of sandwich, Matrigel and 2D cultures. Archives of toxicology 2008. link 25 Katsura N, Ikai I, Mitaka T, Shiotani T, Yamanokuchi S, Sugimoto S et al.. Long-term culture of primary human hepatocytes with preservation of proliferative capacity and differentiated functions. The Journal of surgical research 2002. link 26 Liu K, Dodge R, Glasgow BJ, Layfield LJ. Fine-needle aspiration: comparison of smear, cytospin, and cell block preparations in diagnostic and cost effectiveness. Diagnostic cytopathology 1998. link1097-0339(199807)19:1<70::aid-dc15>3.0.co;2-5) 27 Cossons N, Nielsen TO, Dini C, Tomilin N, Young DB, Riabowol KT et al.. Circular YAC vectors containing a small mammalian origin sequence can associate with the nuclear matrix. Journal of cellular biochemistry 1997. link1097-4644(19971215)67:4<439::aid-jcb3>3.0.co;2-t) 28 Schippers IJ, Moshage H, Roelofsen H, Müller M, Heymans HS, Ruiters M et al.. Immortalized human hepatocytes as a tool for the study of hepatocytic (de-)differentiation. Cell biology and toxicology 1997. link 29 Baum O, Troll S, Hixson DC. The long and the short isoform of cell-CAM 105 show variant-specific modifications in adult rat organs. Biochemical and biophysical research communications 1996. link 30 Baimai V, Trinachartvanit W, Tigvattananont S, Grote PJ, Poramarcom R, Kijchalao U. Metaphase karyotypes of fruit flies of Thailand. I. Five sibling species of the Bactrocera dorsalis complex. Genome 1995. link 31 Jaumot M, Graña X, Giordano A, Reddy PV, Agell N, Bachs O. Cyclin/cdk2 complexes in the nucleus of HeLa cells. Biochemical and biophysical research communications 1994. link 32 Eckl PM. Occurrence and possible consequences of multipolar mitoses in primary cultures of adult rat hepatocytes. Journal of cellular physiology 1993. link 33 Durand-Schneider AM, Bouanga JC, Feldmann G, Maurice M. Microtubule disruption interferes with the structural and functional integrity of the apical pole in primary cultures of rat hepatocytes. European journal of cell biology 1991. link 34 Graeve L, Patzak A, Drickamer K, Rodriguez-Boulan E. Polarized expression of functional rat liver asialoglycoprotein receptor in transfected Madin-Darby canine kidney cells. The Journal of biological chemistry 1990. link 35 Zhou C, Jong A. CDC6 mRNA fluctuates periodically in the yeast cell cycle. The Journal of biological chemistry 1990. link 36 Klose U, Thierau D, Veser U, Schwarz LR. Stimulation of DNA synthesis in carcinogen-induced diploid hepatocytes in vitro. Carcinogenesis 1990. link 37 Matsuguchi T, Okamura S, Kawasaki C, Niho Y. Production of interleukin 6 from human liver cell lines: production of interleukin 6 is not concurrent with the production of alpha-fetoprotein. Cancer research 1990. link 38 Bludau H, Kopun M, Werner D. Cell cycle-dependent expression of nuclear matrix proteins of Ehrlich ascites cells studied by in vitro translation. Experimental cell research 1986. link90551-3) 39 Troyanovsky SM, Bannikov GA, Montesano R, Vasiliev JM. Density-dependent expression of keratins in transformed rat liver cell lines. Cell biology international reports 1986. link90073-1) 40 Godbout R, Gallie BL, Phillips RA. Characterization of a stable, anchorage-dependent clone obtained from a spontaneously transformed mouse cell line. In vitro 1984. link 41 Severin E, Meier EM, Willers R. Flow cytometric analysis of mouse hepatocyte ploidy. I. Preparative and mathematical protocol. Cell and tissue research 1984. link 42 Hlubinová K, Prachar J, Simkovic D. Growth of mammalian cell lines in a spinner culture. Neoplasma 1980. link 43 Barfod IH, Barfod NM. Cell-production rates estimated by the use of vincristine sulphate and flow cytometry. II. Correlation between the cell-production rates of ageing ascites tumours and the number of S phase tumour cells. Cell and tissue kinetics 1980. link 44 Yosida TH, Sagai T. Variation of C-bands in the chromosomes of several subspecies of Rattus rattus. Chromosoma 1975. link